Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 12/20 | 0.35 |
| ▸ | CA9 | Q16790 | 11/20 | 0.35 |
| ▸ | CA1 | P00915 | 10/20 | 0.35 |
| ▸ | CA12 | O43570 | 10/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | GSK3A | P49840 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6735055 | 0.91 | CA12 (0.37) | CA2CA9CA1CA12PTGS2 | |
| SCHEMBL6732148 | 0.90 | HSD11B1 (0.32) | CA2CA9CA1CA12HSD11B1 | |
| SCHEMBL6737064 | 0.89 | HSD11B1 (0.31) | CA2CA9CA1CA12HSD11B1 | |
| SCHEMBL6734008 | 0.88 | PTGS2 (0.39) | CA2CA9CA1CA12PTGS2 | |
| SCHEMBL6732860 | 0.88 | PTGS2 (0.37) | CA2CA9CA1CA12PTGS2 | |
| SCHEMBL6736755 | 0.88 | GSK3A (0.35) | CA2CA9CA1CA12PTGS2 | |
| SCHEMBL6734347 | 0.88 | GSK3A (0.38) | CA2CA9CA1CA12PTGS2 | |
| SCHEMBL6740641 | 0.87 | PTGS2 (0.34) | CA2CA9CA1CA12PTGS2 | |
| SCHEMBL6733589 | 0.87 | L3MBTL1 (0.33) | CA2CA9CA1CA12PTGS2 | |
| SCHEMBL6732553 | 0.87 | TSHR (0.33) | CA2CA9CA1CA12HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6699884-B2 | ANTIINFLAMMATORY CYCLOOXYGENASE INHIBITORS. | PHARMACIA CORPORATION | 2004-03-02 | — | — | US | claimed |
| US-20040138261-A1 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2004-07-15 | — | — | US | disclosed |
| US-6699884-B2 | ANTIINFLAMMATORY CYCLOOXYGENASE INHIBITORS. | PHARMACIA CORPORATION | 2004-03-02 | — | — | US | disclosed |
| US-6673818-B2 | TREATING CYCLOOXYGENASE-2 MEDIATED DISORDERS, SUCH AS ARTHRITIS, PAIN, FEVER AND CANCER | PHARMACIA CORPORATION | 2004-01-06 | — | — | US | disclosed |
| US-20030149078-A1 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2003-08-07 | — | — | US | disclosed |
| US-20030032657-A1 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2003-02-13 | — | — | US | disclosed |
| EP-1251126-A2 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | Pharmacia Corporation (US) | 2002-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138261-A1 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | FPR1, FPR2, FPR3 | CA2 3175/4885CA9 4004/4885CA1 2085/4885 |
| US-20030149078-A1 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | FPR1, FPR2, FPR3 | CA2 3175/4885CA9 4004/4885CA1 2085/4885 |
| US-20030032657-A1 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | FPR1, FPR2, FPR3 | CA2 3175/4885CA9 4004/4885CA1 2085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.